The app denotes the yellow color label for medications (all beta blockers, RASi, and SGLT2i) that patients are not on if there is not enough vitals data to provide a recommendation on the medicine, even if the patient is not on the medicine.
For example, the test patient is not on an SGTL2i (eg, empagliflozin) but the app denotes a yellow label meaning the patient is taking the medicine but not at the target dose.
Reproduction
For all of the beta blockers, RAS inhibitors (ACE inhibitors, ARBs, and ARNI), and SGLT2 inhibitors when the patient does not have enough vital measurements loaded into the app and they have no allergy/intolerance to the medication classes, the coloring scheme is incorrect.
Expected behavior
The color coding on the medication should be blue because the patient is not currently taking the medication.
Additional context
No response
Code of Conduct
[X] I agree to follow this project's Code of Conduct and Contributing Guidelines
Description
The app denotes the yellow color label for medications (all beta blockers, RASi, and SGLT2i) that patients are not on if there is not enough vitals data to provide a recommendation on the medicine, even if the patient is not on the medicine.
For example, the test patient is not on an SGTL2i (eg, empagliflozin) but the app denotes a yellow label meaning the patient is taking the medicine but not at the target dose.
Reproduction
For all of the beta blockers, RAS inhibitors (ACE inhibitors, ARBs, and ARNI), and SGLT2 inhibitors when the patient does not have enough vital measurements loaded into the app and they have no allergy/intolerance to the medication classes, the coloring scheme is incorrect.
Expected behavior
The color coding on the medication should be blue because the patient is not currently taking the medication.
Additional context
No response
Code of Conduct